What is Revance Therapeutics?
Headquartered in Newark, California, Revance Therapeutics is a biotechnology firm dedicated to the development, manufacturing, and commercialization of innovative botulinum toxin-based solutions. Originally founded in 1999 as Essentia Biosystems, the company has evolved into a significant player in both aesthetic and therapeutic medicine. Its primary focus centers on the development of DaxibotulinumtoxinA, a lead drug candidate currently undergoing rigorous Phase III clinical trials for the treatment of glabellar lines, alongside ongoing research for cervical dystonia and plantar fasciitis. By targeting both cosmetic and medical indications, Revance maintains a diversified portfolio that mitigates risk while maximizing the potential for long-term commercial success in the highly competitive biopharma sector.
How much funding has Revance Therapeutics raised?
Revance Therapeutics has raised a total of $532M across 7 funding rounds:
Series A
$1.8M
Series B
$13M
Series C
$43.2M
Series D
$45M
Series E
$33M
Stock Offering
$96M
Debt
$300M
Series A (2003): $1.8M, investors not publicly disclosed
Series B (2004): $13M led by Vivo Capital, Technology Partners, and Essex Woodlands
Series C (2007): $43.2M supported by Medicis Pharmaceutical, Vivo Capital, Technology Partners, Shepherd Ventures, Essex Woodlands, and Palo Alto Investors
Series D (2011): $45M featuring NovaQuest Capital Management, Essex Woodlands, Palo Alto Investors, Vivo Capital, CNF Investments, Technology Partners, and Shepherd Ventures
Series E (2013): $33M backed by NovaQuest, Delphi Ventures, and Essex Woodlands
Stock Issuance/Offering (2014): $96M, investors not publicly disclosed
Debt (2022): $300M led by Athyrium Capital Management
Key Investors in Revance Therapeutics
Essex Woodlands
EW Healthcare Partners is one of the largest and oldest private healthcare investment firms, specializing in growth equity for commercial-stage pharmaceutical and medical device companies.
Vivo Capital
A global healthcare investment firm founded in 1996 that focuses on private and public equity as well as venture capital within the life sciences sector.
Athyrium Capital Management
A leading investment management platform that provides structured financing solutions to companies across the global healthcare and biotechnology industries.
What's next for Revance Therapeutics?
Looking ahead, the strategic deployment of the $300M investment will likely focus on the finalization of clinical trials and the subsequent commercialization of its lead assets. As the company transitions from a development-heavy entity to a commercial-stage powerhouse, the focus will shift toward market penetration and the scaling of manufacturing capabilities. The ongoing support from seasoned healthcare investors suggests a clear path toward sustained growth and potential market dominance in the botulinum toxin space. Future milestones will likely involve regulatory approvals and the expansion of the company's therapeutic footprint, ensuring that Revance remains at the forefront of medical innovation.
See full Revance Therapeutics company page
